January 16

On this day in 1988, Jimmy “The Greek” Snyder was fired as a CBS sports commentator one day after telling a TV station in Washington DC that, during the era of slavery, blacks had been bred to produce stronger offspring, and were naturally superior athletes.

American opera singer

Marilyn Horne, in full Marilyn Bernice Horne, (born Jan. 16, 1934, Bradford, Pa., U.S.), American mezzo-soprano noted for the seamless quality and exceptional range and flexibility of her voice, especially in coloratura roles by Gioacchino Rossini and George Frideric Handel. She was also instrumental in reviving interest in their lesser-known operas.

1547 – Ivan the Terrible was crowned Czar of Russia.

1572 – The Duke of Norfolk was tried for treason for complicity in the Ridolfi plot to restore Catholicism in England. He was executed on June 2.

1759 – The British Museum opened.

1809 – The British defeated the French at the Battle of Corunna, in the Peninsular War.

1866 – Mr. Everett Barney patented the metal screw, clamp skate.

1883 – The United States Civil Service Commission was established as the Pendleton Act went into effect.

1896 – The first five-player college basketball game was played at Iowa City, IA.

1900 – The U.S. Senate consented to the Anglo-German treaty of 1899, by which the U.K. renounced rights to the Samoan islands.

1919 – The 18th Amendment to the U.S. Constitution, which prohibited the sale or transportation of alcoholic beverages, was ratified. It was later repealed by the 21st Amendment.

1920 – Prohibition went into effect in the U.S.

1920 – The motion picture “The Kid” opened.

1925 – Leon Trotsky was dismissed as Chairman of the Revolutionary Council of the USSR.

1939 – The “I Love a Mystery” debuted on NBC’s West-Coast outlets.

1944 – General Dwight D. Eisenhower took command of the Allied invasion force in London.

1961 – Mickey Mantle signed a contract that made him the highest paid baseball player in the American League at $75,000 for the 1961 season.

1964 – “Hello Dolly!” opened at the St. James Theatre in New York City.

1970 – Colonel Muammar el-Quaddafi became virtual president of Libya.

1970 – Buckminster Fuller, the designer of the geodesic dome, was awarded the Gold Medal of the American Institute of Architects.

1979 – The Shah of Iran and his family fled Iran for Egypt.

1982 – Britain and the Vatican resumed full diplomatic relations after a break of over 400 years.

1985 – “Playboy” magazine announced its 30-year tradition of stapling centerfold models in the bellybutton and elsewhere would come to an immediate end.

1988 – Jimmy “The Greek” Snyder was fired as a CBS sports commentator one day after telling a TV station in Washington, DC, that, during the era of slavery, blacks had been bred to produce stronger offspring.

1998 – Researchers announce that an altered gene helped to defend against HIV.

1991 – The White House announced the start of Operation Desert Storm. The operation was designed to drive Iraqi forces out of Kuwait.

1992 – Officials of the government of El Salvador and rebel leaders signed a pact in Mexico City ending 12 years of civil war. At least 75,000 people were killed during the fighting.

1998 – The first woman to enroll at Virginia Military Institute withdrew from the school.

1998 – NASA officially announced that John Glenn would fly aboard the space shuttle Discovery in October.

1998 – It was announced that Texas would receive $15.3 billion in a tobacco industry settlement. The payouts were planned to take place over 25 years.

1998 – Three federal judges secretly granted Kenneth Starr authority to probe whether U.S. President Clinton or Vernon Jordan urged Monica Lewinsky to lie about her relationship with Clinton.

2000 – Ricardo Lagos was elected Chile’s first socialist president since Salvador Allende.

2002 – U.S. Attorney General John Ashcroft announced that John Walker Lindh would be brought to the United States to face trial. He was charged in U.S. District Court in Alexandria, VA, with conspiracy to kill U.S. citizens, providing support to terrorist organizations, and engaging in prohibited transactions with the Taliban of Afghanistan.

2002 – The U.N. Security Council unanimously adopted sanctions against Osama bin Laden, his terror network and the remnants of the Taliban. The sanctions required that all nations impose arms embargoes and freeze their finances.

2009 – The iTunes Music Store reached 500 million applications downloaded.

on-this-day.com

** 001-2021, Courage Production, LLC. Recalls Ready-to-Eat, Fully Cooked Polish Sausage Products due to Misbranding and an Undeclared Allergen (Jan 2, 2021)

** 029-2020, Perfect Pasta Inc. Recalls Frozen Meat and Poultry Products Produced Without Benefit of Inspection (Dec 19, 2020)

** 001-2021, Courage Production, LLC. Recalls Ready-to-Eat, Fully Cooked Polish Sausage Products due to Misbranding and an Undeclared Allergen (Jan 2, 2021)

** Nestlé Prepared Foods, a Mt. Sterling, Ky. establishment, is recalling approximately 762,615 pounds of not-ready-to-eat (NRTE) pepperoni hot pockets product that may be contaminated with extraneous materials, specifically pieces of glass and hard plastic, the U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) announced today. December

The frozen NRTE pepperoni hot pockets product was produced from Nov. 13, 2020 through Nov. 16, 2020. The product has a shelf life of 14 months. The following product is subject to recall: [View Labels (PDF Only)]:

• 54-oz carton packages containing 12 “Nestlé HOT POCKETS BRAND SANDWICHES: PREMIUM PEPPERONI MADE WITH PORK, CHICKEN & BEEF PIZZA GARLIC BUTTERY CRUST” with a “BEST BEFORE FEB 2022” date and lot codes 0318544624, 0319544614, 0320544614, and 0321544614.

The product subject to recall bears establishment number “EST. 7721A” inside the USDA mark of inspection. The product was shipped to retail locations nationwide.

The problem was discovered when the firm received four consumer complaints of extraneous material in the pepperoni hot pocket product.

The firm has received one report of a minor oral injury associated with consumption of this product. FSIS has received no additional reports of injury or illness from consumption of this product. Anyone concerned about an injury or illness should contact a healthcare provider.

FSIS is concerned that some product may be frozen and in consumers’ freezers. Consumers who have purchased this product are urged not to consume it. This product should be thrown away or returned to the place of purchase.

FSIS routinely conducts recall effectiveness checks to verify recalling firms notify their customers of the recall and that steps are taken to make certain that the product is no longer available to consumers. When available, the retail distribution lists will be posted on the FSIS website at www.fsis.usda.gov/recalls.

Consumers with questions about the recall can contact Nestlé consumer services at (800) 350-5016. Members of the media with questions about the recall can contact Dana Stambaugh, Corporate Communications for Nestlé at (571) 457-3803 or at Dana.Stambaugh@us.nestle.com.

** Precision Dose, Inc. is voluntarily recalling all lots of Chlorhexidine Gluconate Oral Rinse USP, 0.12%, 15mL Unit Dose Cups bearing an expiration date from 1/31/2021 – 02/28/2022 (see specific lots below) to the consumer level. Precision Dose, Inc. was notified by the manufacturer of the product, Sunstar Americas, Inc., that this product may be contaminated with the bacteria Burkholderia lata.

From information provided by the manufacturer, Sunstar Americas, Inc., use of the defective product in the immunocompetent host may result in oral and, potentially, systemic infections requiring antibacterial therapy. In the most at-risk populations, the use of the defective product may result in life-threatening infections, such pneumonia and bacteremia. To date, no adverse events have been reported to Precision Dose, Inc. related to this recall.

The prescription oral rinse product, available through healthcare professionals only, is indicated for use as part of a professional program for the treatment of gingivitis and the product impacted is:

• Distributed in cases each containing 3 shrink-wrapped plastic trays each with 10 unit dose cups, 30-pack. NDC 68094-028-62
• Distributed in cases each containing 10 shrink-wrapped plastic trays each with 10 unit dose cups, 100-pack. NDC 68094-028-61

Chlorhexidine Gluconate Oral Rinse was distributed nationwide in the USA to pharmaceutical wholesalers.

Precision Dose, Inc. is notifying its consignees directly and is arranging for return of all recalled product. Patients, pharmacies, and healthcare facilities in possession of these products should stop using and dispensing immediately.

Consumers with questions regarding this recall can contact Precision Dose, Inc. at 1 (800) 397-9228 (Monday-Friday, 8:00 AM to 4:30 PM Central Time) or by email to customercare@precisiondose.com. Consumers should contact their physician or healthcare provider if they have experienced problems that may be related to using this drug product.

Affected products and lot numbers follow below:

AFFECTED LOTS-Chlorhexidine Gluconate Oral Rinse USP, 0.12%

LOT NUMBER	EXPIRATION DATE	NDC NUMBER
502037	01/31/2021	68094-028-61 68094-028-62
502040	01/31/2021	68094-028-61 68094-028-62
502043	01/31/2021	68094-028-61 68094-028-62
502494	08/31/2021	68094-028-61 68094-028-62
502757	08/31/2021	68094-028-61
502677	09/30/2021	68094-028-61
502693	10/31/2021	68094-028-61
502728	10/31/2021	68094-028-61
502759	10/31/2021	68094-028-62
502771	11/30/2021	68094-028-61 68094-028-62
502784	11/30/2021	68094-028-61
502824	12/31/2021	68094-028-61
502925	02/28/2022	68094-028-61

Patients should contact their physician or healthcare provider if they have additional questions or concerns. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

• Complete and submit the report Online
• Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

** Weis Markets today said it has issued a recall for:

• 10,869 containers of Weis Quality Cookies and Cream Ice Cream (48 oz.), and
• 502 bulk containers of Klein’s Vanilla Dairy Ice Cream (3 gallon)

because the products may be contaminated with extraneous material, specifically metal filling equipment parts. There has been one report of a customer who discovered an intact piece of metal equipment in the Weis Quality Cookies and Cream Ice Cream (48 oz). There is concern of an additional piece of equipment present in the ice cream product(s) possibly presenting a choking hazard.

The Weis Quality Cookies and Cream Ice Cream (in 48 oz. containers) product has been removed from sale. It was sold in 197 Weis Markets’ stores in Pennsylvania, Maryland, Virginia, New Jersey, New York, Delaware and West Virginia.

The Weis Quality Cookies and Cream ice cream is packaged in a scround 48- ounce container with a UPC of 041497-01253 and with a sell by date of 10/28/21. This was produced on 10/28/2020 and released for sale on 10/29/2020. The sell by date is located on the bottom of the container. An example of the label has been included with this release. Customers who have purchased this product may return it for a full refund.

The Klein’s Vanilla bulk ice cream is packaged in 3-gallon containers with a code stamp of 0302 and are not for retail sale. This product was sold to one retail establishment in New York and has been removed from sale.

Additional ice cream products packaged on 10/28/2020 included:

• Klein’s Cookies and Cream Dairy Bulk – 665 containers, and
• Nelson’s Graham Slam Bulk – 286 containers

These items are packaged in 3-gallon bulk containers with a code stamp of 0302 and are not for retail sale. They were stored in a warehouse and have not been distributed.

Customers requiring additional information may contact Weis Customer Service at 1-866-999-9347 Monday through Friday 8am-5pm EST.

** Dole Fresh Vegetables, Inc. is voluntarily recalling a limited number of cases of Dole™ Sesame Asian Chopped Salad Kit.

Description	UPC	Best If Used By Date	Lot Code
Dole™ Sesame Asian Chopped Salad	0-71430-00035-9	01-15-21	B364016 B364017

This voluntary recall is due to possible undeclared allergens (egg) in Dole™ Sesame Asian Chopped Salad Kit. The dressing and topping kit (masterpack) designed for a different Dole product was unintentionally used during a portion of the production of the salad. Dole Fresh Vegetables, Inc. is coordinating closely with regulatory officials. No illnesses or allergic reactions have been reported to date in association with the recall. However, people who have an allergy to eggs may have a serious or life-threatening allergic reaction if they consume this product or products containing eggs.

The product lot code and Best if Used by Date is located on the upper right corner of each bag and the UPC code is located on the bottom right corner of the back of each bag. The impacted products were distributed in AK, CA, ID, KS, MO, OK, OR, TX AND UT. Consumers are advised to check product they have in their homes and discard any product matching the production description, UPC codes, product lot code and Best if Used by Date listed above.

No other Dole products are included in the recall. Only Dole™ Sesame Asian Chopped Salad Kit with the exact UPC code, lot code and Best if Used by Date identified above, are included in the recall. Consumers who have any remaining product should not consume it, but rather discard it. Retailers and consumers with questions may call the Dole Consumer Center at 1-800-356-3111, which is open 24 hours a day.

Nostrum Laboratories, Inc. is voluntarily recalling one lot of Metformin HCl Extended Release Tablets, USP 750 mg (generic equivalent to Glucophage Tablets) to the consumer level. The Metformin HCl Extended Release Tablets, USP 750 mg (generic equivalent to Glucophage Tablets) have been found to contain levels of nitrosamine impurities above the ADI limit of 96 ng/day as published in the FDA Guidance Document issued September, 2020. This is an expansion of the recall initially announced on November 2, 2020.

NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables. To date, Nostrum Laboratories, Inc. has not received any reports of adverse events related to this recall.

The product is indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus and is packaged in HDPE bottles of 100 tablets, under NDC 29033-056-01. The affected Metformin HCl Extended Release Tablets, USP 750 mg (generic equivalent to Glucophage Tablets) lot is listed in the table below. The product can be identified as an off-white oblong tablet debossed with “NM7”. Metformin HCl Extended Release Tablets, USP 750 mg (generic equivalent to Glucophage Tablets) was distributed Nationwide to wholesalers.

Product Description	NDC	Lot Number	Expiry Dates
Metformin HCl Extended Release Tablets, USP 750 mg (generic equivalent to Glucophage Tablets)	29033-056-01	MET200501	07/2022

Nostrum Laboratories, Inc. is notifying its distributors by letter and is arranging for return of all recalled products. Pharmacies that have Metformin HCl Extended Release Tablets, USP 750 mg (generic equivalent to Glucophage Tablets) which is being recalled should return to place of purchase. Consumers should consult a healthcare professional to obtain a replacement or a different treatment option. It could be dangerous for patients with type 2 diabetes to stop taking their metformin without first talking to their healthcare professional. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking this drug product.

Consumers with medical questions regarding this recall can contact Nostrum Laboratories, Inc. Medical Affairs at phone number 816-308-4941 or email quality@nostrumpharma.com Monday through Friday from 8 am – 5 pm CST. Consumers should contact their physician or pharmacy for further medical advice.

** Out of an abundance of caution, EVR Foods, INC, parent company to Lavva, is issuing a voluntary recall on its 5.3 ounce Blueberry Plant-Based Yogurt with expiration date 2/21/21. While this SKU and date code cleared strict quality assurance protocols, recent testing indicates a potential mold contamination. No other Lavva products are affected by the recall.

This plant-based yogurt was produced at a manufacturing facility in Norwich, NY, and has only been linked to the single date code. There have been no confirmed illnesses to date.

The recalled Blueberry Plant-Based Yogurts were distributed to retail stores nationwide. The product comes in a 5.3 ounce, colorful plastic cup with a foil lid, marked with lot #022121 on the bottom of the cup which is also used as the expiration date of the product.

Consumers are urged not to eat the product subject to the recall. Anyone who purchased the SKU may return it to the place of purchase for a full refund. Consumers with questions about the recall can reach out to hello@lovvelavva.com or 833-885-2882 between 9 a.m. to 5 p.m. EST Monday through Friday. The Food & Drug Administration (FDA) has been notified of this recall and is assisting with the process.

About Lavva

** FSIS Issues Public Health Alert for Not-Ready-to-Eat, Heat Treated, Not Fully Cooked Chicken Enchilada Products Due to Misbranding and an Undeclared AllergenThe U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) is issuing a public health alert for approximately 43 pounds of not-ready-to-eat (NRTE), heat treated, not fully cooked chicken enchilada products due to misbranding and an undeclared allergen.

** Fresenius Kabi USA is voluntarily recalling a single lot of Ketorolac Tromethamine Injection, USP, 30 mg/mL, 1 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter. Particulate matter was found in reserve sample vials. No adverse event reports have been received for the recalled lot, which was produced and sold in 2019.

Administration of products containing particulate matter could obstruct blood vessels and result in local irritation of blood vessels, swelling at the site of injection, a mass of tissue that could become inflamed and infected, blood clots traveling to the lung, scarring of the lung tissues, and allergic reactions that could lead to life-threatening consequences.

Ketorolac Tromethamine, a nonsteroidal anti-inflammatory drug, is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level. The total combined duration of use of oral Ketorolac Tromethamine and Ketorolac Tromethamine Injection should not exceed 5 days.

Listed below is a table of the recalled lot distributed nationwide in the United States to wholesalers, distributors, hospitals, and pharmacies between March 28, 2019 and September 3, 2019. An image of the label is also included below.

Product Name/Product size	NDC Number	Product Code	Batch Number	Expiration Date	First Ship Date	Last Ship Date
Ketorolac Tromethamine Injection, USP, 30 mg / mL, 1 mL fill in a 2 mL amber vial	63323-162-01	160201	6121083	02/2021	03/28/2019	09/03/2019

Fresenius Kabi is notifying its distributors and customers by letter and asking customers and distributors to check their stock immediately and to quarantine and discontinue the use and distribution of any affected product. Distributors should notify their customers and direct them to quarantine and discontinue distributing or dispensing the affected lot, and to return the product to Fresenius Kabi. The recall letter and response form are available at https://www.fresenius-kabi.com/us/pharmaceutical-product-updates.External Link Disclaimer

Customers with questions regarding this recall may contact Fresenius Kabi at 1-866-716-2459 Monday through Friday, during the hours of 8:00 a.m. to 5:00 p.m. Central Time. Consumers should contact their physician or health care provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

** Precision Dose, Inc. is voluntarily recalling all lots of Chlorhexidine Gluconate Oral Rinse USP, 0.12%, 15mL Unit Dose Cups bearing an expiration date from 1/31/2021 – 02/28/2022 (see specific lots below) to the consumer level. Precision Dose, Inc. was notified by the manufacturer of the product, Sunstar Americas, Inc., that this product may be contaminated with the bacteria Burkholderia lata.

From information provided by the manufacturer, Sunstar Americas, Inc., use of the defective product in the immunocompetent host may result in oral and, potentially, systemic infections requiring antibacterial therapy. In the most at-risk populations, the use of the defective product may result in life-threatening infections, such pneumonia and bacteremia. To date, no adverse events have been reported to Precision Dose, Inc. related to this recall.

The prescription oral rinse product, available through healthcare professionals only, is indicated for use as part of a professional program for the treatment of gingivitis and the product impacted is:

• Distributed in cases each containing 3 shrink-wrapped plastic trays each with 10 unit dose cups, 30-pack. NDC 68094-028-62
• Distributed in cases each containing 10 shrink-wrapped plastic trays each with 10 unit dose cups, 100-pack. NDC 68094-028-61

Chlorhexidine Gluconate Oral Rinse was distributed nationwide in the USA to pharmaceutical wholesalers.

Precision Dose, Inc. is notifying its consignees directly and is arranging for return of all recalled product. Patients, pharmacies, and healthcare facilities in possession of these products should stop using and dispensing immediately.

Consumers with questions regarding this recall can contact Precision Dose, Inc. at 1 (800) 397-9228 (Monday-Friday, 8:00 AM to 4:30 PM Central Time) or by email to customercare@precisiondose.com. Consumers should contact their physician or healthcare provider if they have experienced problems that may be related to using this drug product.

Affected products and lot numbers follow below:

AFFECTED LOTS-Chlorhexidine Gluconate Oral Rinse USP, 0.12%

LOT NUMBER	EXPIRATION DATE	NDC NUMBER
502037	01/31/2021	68094-028-61 68094-028-62
502040	01/31/2021	68094-028-61 68094-028-62
502043	01/31/2021	68094-028-61 68094-028-62
502494	08/31/2021	68094-028-61 68094-028-62
502757	08/31/2021	68094-028-61
502677	09/30/2021	68094-028-61
502693	10/31/2021	68094-028-61
502728	10/31/2021	68094-028-61
502759	10/31/2021	68094-028-62
502771	11/30/2021	68094-028-61 68094-028-62
502784	11/30/2021	68094-028-61
502824	12/31/2021	68094-028-61
502925	02/28/2022	68094-028-61

Patients should contact their physician or healthcare provider if they have additional questions or concerns. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

January 15 – 19 now days